Well, one thing I’d say though is that when you look at when a provider is being challenged on something that’s related to an LCD, it’s often overturned at the administrative law judge level because it doesn’t hold any weight, because the physician’s prerogative is to take care o...
Veracyte Inc has received a final Medicare local coverage determination (LCD) for the Envisia Genomic Classifier, a genomic diagnostic for idiopathic pulmonary fibrosis (IPF). The policy was issued through the Palmetto GBA MolDx program and will become effective April 1, 2019, making the Envisia ...